Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Summary - MDSpire
Advertisement
Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas
To evaluate the long-term effectiveness and safety of lebrikizumab in treating moderate-to-severe atopic dermatitis, particularly in head and neck areas, in a real-world setting, emphasizing its clinical implications.
Approach:
Key Findings:
Lebrikizumab demonstrated sustained effectiveness over 52 weeks, with EASI scores improving significantly.
Clinical responses were maintained with Q4W dosing, regardless of head and neck involvement, with specific numerical data.
Patients reported significant improvements in EASI scores, with detailed percentages.
Interpretation:
Lebrikizumab is effective and safe for long-term treatment of moderate-to-severe atopic dermatitis, including in challenging head and neck areas, supporting its use in clinical practice.
Limitations:
Retrospective design may limit data completeness and generalizability, particularly due to the small sample size for head and neck involvement analysis at week 52.
Conclusion:
Lebrikizumab is a promising treatment option for patients with moderate-to-severe atopic dermatitis, showing sustained efficacy and safety in a real-world setting, highlighting its potential role in clinical practice.
by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
